Ann: Approval Received for Distribution of CannEpil into Ireland, page-15

Failure of YuShop deal and VC deal, high directors' wages, 1.37 BILLION shares issued + performance shares issued , questionable Cannaglobal valuation, huge financial net loss in financial year etc...

And as I said many times before, if MXC's Cannepil double the price of its competitor, the business is just not sustainable no matter how many "distribution contract" signed. It is because ultimately no patients (or very little) will be willing to paying double to get similar/same stuff. That's probably the reason why they just keep saying how many prescriptions are written, but stay quiet on how many patients actually fill the prescriptions.

Uprampers can keep ignoring my advice but the share price and the market has proven I am correct since late 2017. (Falling 70% since I sold all my MXC shares).